BC
ARQT icon

Bridgefront Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Bridgefront Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Buy
+11,825
New +$275K 0.08% 372

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bridgefront Capital's ARQT Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 11,825 shares worth $310K. The stake represents 0.08% of the portfolio and ranks #372 among its holdings.

272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Bridgefront Capital held 11,825 shares of Arcutis Biotherapeutics worth $310K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Bridgefront Capital position in Q2 2026.
  • Arcutis Biotherapeutics made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #372 holding.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.